Weight-Loss drug tirzepatide takes on heart flutter in new trial
NCT ID NCT06802081
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study at the Cleveland Clinic will test whether the weight-loss drug tirzepatide (Zepbound) can help people with obesity and atrial fibrillation (AFib). About 100 participants will receive weekly injections of tirzepatide or a placebo for up to 12 months. The main goal is to see if weight loss reduces the total time spent in AFib and improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirzepatide (Zepbound)
What this could lead to
If successful, this could show that weight loss with tirzepatide helps control atrial fibrillation symptoms and reduce time spent in AFib.
What could go wrong
This is a small, early-phase trial (100 people) at one center. Results may not apply to everyone, and tirzepatide has side effects like nausea and vomiting. The study is not designed to prove long-term safety or efficacy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••